Research
Hormonal
Abdominal obesity is related to an increased likelihood of undergoing prostatectomy for benign prostatic hyperplasia (OR = 2.38, 95% CI 1.42-3.99) for men with a waist circumference ≥ 43 inches compared to those with a waist circumference < 35 inches.
Practitioners should consider abdominal obesity as a significant risk factor for benign prostatic hyperplasia and potential surgical intervention.
StrongSupportsmedium confidence
After adjustment for age, smoking, and body mass index, abdominal obesity was related to prostatectomy (odds ratio (OR) = 2.38, 95% confidence interval (CI) 1.42-3.99, for those with a waist circumference > or = 43 inches (109 cm) relative to those with a waist circumference < 35 inches (89 cm); p trend < 0.0001).
Why this rating
The study is based on a large cohort with clear statistical analysis.
Source
Obesity and Benign Prostatic Hyperplasia
Edward L. Giovannucci et al. · American Journal of Epidemiology · 1994
DOI 10.1093/oxfordjournals.aje.a117206
cohort · n=25892Cited 229×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →